A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab

British Journal of Haematology

Volumn 170, Issue 2, 2015, Pages 208-217

  Clark, William F ^a   Rock, Gail ^b   Barth, David ^c   Arnold, Donald M ^d   Webert, Kathyrn E ^d   Yenson, Paul R ^e   Kelton, John G ^d   Li, Lihua ^a   Foley, Steven R ^d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

ADAMTS13; Plasma exchange; Rituximab; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura

Indexed keywords

IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; RITUXIMAB;

ADULT; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PLASMAPHERESIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENT DISEASE; TIME; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84934434760     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13408     Document Type: Article

References (45)

1. Altman, D.G. (2001) The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Annals of Internal Medicine, 134, 663.
2. Bandarenko, N. & Brecher, M.E. (1998) United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. Journal of Clinical Apheresis, 13, 133-141.
3. Bell, W.R., Braine, H.G., Ness, P.M. & Kickler, T.S. (1991) Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. The New England Journal of Medicine, 325, 398-403.
4. Bianchi, V., Robles, R., Alberio, L., Furlan, M. & Lämmle, B. (2002) Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood, 100, 710-713.
5. Caramazza, D., Quintini, G., Abbene, I., Malato, A., Saccullo, G., Lo Coco, L., Di Trapani, R., Palazzolo, R., Barone, R., Mazzola, G., Rizzo, S., Ragonese, P., Aridon, P., Abbadessa, V. & Siragusa, S. (2010) Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. Transfusion, 50, 2753-2760.
6. Carreras, L., Romero, R., Requesens, C., Oliver, A.J., Carrera, M., Clavo, M. & Alsina, J. (1981) Familial hypocomplementemic hemolytic uremic syndrome with HLA-A3, B7 haplotype. JAMA: The Journal of the American Medical Association, 245, 602-604.
7. Cataland, S.R. & Wu, H.M. (2013) Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies. European Journal of Internal Medicine, 24, 486-491.
8. Clark, W.F., Rock, G.A., Buskard, N., Shumak, K.H., LeBlond, P., Anderson, D. & Sutton, D.M. (1999) Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Annals of Internal Medicine, 131, 453-462.
9. Coppo, P., Bengoufa, D., Veyradier, A., Wolf, M., Bussel, A., Millot, G.A., Malot, S., Heshmati, F., Mira, J.-P., Boulanger, E., Galicier, L., Durey-Dragon, M.-A., Frémeaux-Bacchi, V., Ramakers, M., Pruna, A., Bordessoule, D., Gouilleux, V., Scrobohaci, M.-L., Vernant, J.-P., Moreau, D., Azoulay, E., Schlemmer, B., Guillevin, L. & Lassoued, K.; Réseau d'Etude des Microangiopathies Thrombotiques de l'Adulte. (2004) Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine, 83, 233-244.
10. Coppo, P., Schwarzinger, M., Buffet, M., Wynckel, A., Clabault, K., Presne, C., Poullin, P., Malot, S., Vanhille, P., Azoulay, E., Galicier, L., Lemiale, V., Mira, J.-P., Ridel, C., Rondeau, E., Pourrat, J., Girault, S., Bordessoule, D., Saheb, S., Ramakers, M., Hamidou, M., Vernant, J.P., Guidet, B., Wolf, M. & Veyradier, A.; French Reference Center for Thrombotic Microangiopathies. (2010) Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS ONE, 5, e10208.
11. De la Rubia, J., Moscardó, F., Gómez, M.J., Guardia, R., Rodríguez, P., Sebrango, A., Zamora, C., Debén, G., Goterris, R., López, R., Peña, F., Pujol, M., Vidaller, A., Del Río-Garma, J. & Sanz, M.A. (2010) Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study. Transfusion and Apheresis Science, 43, 299-303.
12. Dervenoulas, J., Tsirigotis, P., Bollas, G., Pappa, V., Xiros, N., Economopoulos, T., Pappa, M., Mellou, S., Kostourou, A., Papageorgiou, E. & Raptis, S.A. (2000) Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases. Annals of Hematology, 79, 66-72.
13. Elliott, M.A., Heit, J.A., Pruthi, R.K., Gastineau, D.A., Winters, J.L. & Hook, C.C. (2009) Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. European Journal of Haematology, 83, 365-372.
14. Fakhouri, F. & Frémeaux-Bacchi, V. (2007) Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura?. Nature Clinical Practice. Nephrology, 3, 679-687.
15. Foley, S.R., Webert, K., Arnold, D.M., Rock, G.A., Clark, W.F., Barth, D. & Sutton, D.M. (2009) A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Kidney International. Supplement, 75, S55-S58.
16. Forzley, B.R., Sontrop, J.M., Macnab, J.J., Chen, S. & Clark, W.F. (2008) Treating TTP/HUS with plasma exchange: a single centre's 25-year experience. British Journal of Haematology, 143, 100-106.
17. Furlan, M., Robles, R., Solenthaler, M., Wassmer, M., Sandoz, P. & Lämmle, B. (1997) Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood, 89, 3097-3103.
18. Furlan, M., Robles, R., Galbusera, M., Remuzzi, G., Kyrle, P.A., Brenner, B., Krause, M., Scharrer, I., Aumann, V., Mittler, U., Solenthaler, M. & Lämmle, B. (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. The New England Journal of Medicine, 339, 1578-1584.
19. George, J.N. (2006) Clinical practice. Thrombotic thrombocytopenic purpura. The New England Journal of Medicine, 354, 1927-1935.
20. George, J.N., Kremer Hovinga, J.A., Terrell, D.R., Vesely, S.K. & Lämmle, B. (2008) The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: the Swiss connection. European Journal of Haematology, 80, 277-286.
21. Jasti, S., Coyle, T., Gentile, T., Rosales, L. & Poiesz, B. (2008) Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. Journal of Clinical Apheresis, 23, 151-156.
22. Kremer Hovinga, J.A., Vesely, S.K., Terrell, D.R., Lämmle, B. & George, J.N. (2010) Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood, 115, 1500-1511; quiz 1662.
23. Levandovsky, M., Harvey, D., Lara, P. & Wun, T. (2008) Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients. Journal of Hematology & Oncology, 1, 23.
24. Lian, E.C.-Y. (2005) Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond. Seminars in Thrombosis and Hemostasis, 31, 625-632.
25. Ling, H.T., Field, J.J. & Blinder, M.A. (2009) Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. American Journal of Hematology, 84, 418-421.
26. Loirat, C. & Frémeaux-Bacchi, V. (2011) Atypical hemolytic uremic syndrome. Orphanet Journal of Rare Diseases, 6, 60.
27. Lotta, L.A., Mariani, M., Consonni, D., Mancini, I., Palla, R., Maino, A., Vucelic, D., Pizzuti, M., Mannucci, P.M. & Peyvandi, F. (2010) Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. British Journal of Haematology, 151, 488-494.
28. Moake, J.L. (2002) Thrombotic microangiopathies. The New England Journal of Medicine, 347, 589-600.
29. Moake, J.L., Rudy, C.K., Troll, J.H., Weinstein, M.J., Colannino, N.M., Azocar, J., Seder, R.H., Hong, S.L. & Deykin, D. (1982) Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. The New England Journal of Medicine, 307, 1432-1435.
30. Noris, M., Ruggenenti, P., Perna, A., Orisio, S., Caprioli, J., Skerka, C., Vasile, B., Zipfel, P.F. & Remuzzi, G. (1999) Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purp. Journal of the American Society of Nephrology: JASN, 10, 281-293.
31. Porta, C., Caporali, R. & Montecucco, C. (1999) Thrombotic thrombocytopenic purpura and autoimmunity: a tale of shadows and suspects. Haematologica, 84, 260-269.
32. Rieger, M., Ferrari, S., Kremer Hovinga, J.A., Konetschny, C., Herzog, A., Koller, L., Weber, A., Remuzzi, G., Dockal, M., Plaimauer, B. & Scheiflinger, F. (2006) Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thrombosis and Haemostasis, 95, 212-220.
33. Rock, G.A., Shumak, K.H., Buskard, N.A., Blanchette, V.S., Kelton, J.G., Nair, R.C. & Spasoff, R.A. (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. The New England Journal of Medicine, 325, 393-397.
34. Rock, G., Clark, W.F., Anderson, D., Benny, B., Sutton, D., Leblond, P., Sternbach, M. & Sontrop, J. (2013) ADAMTS-13 may not predict disease or outcome in patients with Thrombotic Thrombocytopenic Purpura. Thrombosis Research, 131, 308-312.
35. Sadler, J.E., Moake, J.L., Miyata, T. & George, J.N. (2004) Recent advances in thrombotic thrombocytopenic purpura. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2004, 407-423.
36. Scully, M., Yarranton, H., Liesner, R., Cavenagh, J., Hunt, B., Benjamin, S., Bevan, D., Mackie, I. & Machin, S. (2008) Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. British Journal of Haematology, 142, 819-826.
37. Scully, M., McDonald, V., Cavenagh, J., Hunt, B.J., Longair, I., Cohen, H. & Machin, S.J. (2011) A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood, 118, 1746-1753.
38. Shumak, K.H., Rock, G.A. & Nair, R.C. (1995) Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Annals of Internal Medicine, 122, 569-572.
39. Stühlinger, W., Kourilsky, O., Kanfer, A. & Sraer, J.D. (1974) Letter: haemolytic-uraemic syndrome: evidence for intravascular C3 activation. Lancet, 2, 788-789.
40. Tsai, H.-M. (2003) Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Journal of the American Society of Nephrology: JASN, 14, 1072-1081.
41. Tsai, H.-M. (2007) The kidney in thrombotic thrombocytopenic purpura. Minerva Medica, 98, 731-747.
42. Tsai, H.M. & Lian, E.C. (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. The New England Journal of Medicine, 339, 1585-1594.
43. Tun, N.M. & Villani, G.M. (2012) Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis. Journal of Thrombosis and Thrombolysis, 34, 347-359.
44. Willis, M.S. & Bandarenko, N. (2005) Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease? Seminars in Thrombosis and Hemostasis, 31, 700-708.
45. Zheng, X., Pallera, A.M., Goodnough, L.T., Sadler, J.E. & Blinder, M.A. (2003) Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Annals of Internal Medicine, 138, 105-108.